Carisma Therapeutics

Yahoo Finance • 8 months ago

Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented preclinical proof of concept data in liver fibrosis at ASGCT; expects to nominate a development candidate in the first qua... Full story